Guilford to Webcast Conference Call on June 21, 2004

Guilford to Webcast Conference Call on June 21, 2004 


BALTIMORE, June 18  /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc.
(NASDAQ:GLFD) announced today that it will host a conference call to discuss
its license agreement with Symphony Neuro Development Company (SNDC) relating
to U.S. rights to GPI 1485, as announced on June 18, 2004. Craig Smith,
Chairman, President and Chief Executive Officer of Guilford, will host the
call.

   What:  Guilford Corporate Update conference call

   When:  Monday, June 21 at 11:00 a.m. Eastern Time

   Where: http://www.guilfordpharm.com/

   How:   Dial-in to 1-800-915-4836 (U.S.) or 1-973-317-5319
          (international) to listen to the call.  In addition to the live
          call, there will be a 24-hour audio archive that may be accessed
          by dialing 1-800-428-6051 (U.S.) or 1-973-709-2089
          (international). The conference ID number is 362451.

          Or access the live call or the fourteen-day archive on the
          Internet by logging on to http://www.guilfordpharm.com/. Please
          connect to Guilford's website at least 15 minutes prior to the
          conference call to ensure adequate time for any software download
          that may be needed to access the webcast.

  About Guilford


Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the
research, development and commercialization of products that target the
hospital market. Presently, Guilford markets two commercial products,
GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the treatment
of brain cancer, and AGGRASTAT(R) Injection (tirofiban hydrochloride), a
glycoprotein GP IIb/IIIa receptor antagonist used for the treatment of acute
coronary syndrome (ACS). Guilford's product pipeline includes a novel
anesthetic, AQUAVAN(R) Injection. For additional information about GLIADEL(R)
Wafer, please visit http://www.guilfordpharm.com/ under Products / Marketed
Products / GLIADEL; and for AGGRASTAT(R), please see http://www.aggrastat.com/.

   Contact:

   Guilford: Stacey Jurchison
   Director, Corporate Communications
   410-631-5022  http://www.guilfordpharm.com/

DATASOURCE: Guilford Pharmaceuticals Inc.



CONTACT:  Stacey Jurchison, Director, Corporate Communications, Guilford

Pharmaceuticals, [phone]



Web site:  http://www.guilfordpharm.com/



Company News On-Call:  http://www.prnewswire.com/comp/112882.html

Copyright